DOV Pharmaceutical has announced the initiation of a Phase Ib
clinical trial, which investigates the potential of its triple
reuptake inhibitor candidate for treating depression. The drug's
mechanism of action inhibits three...
The first melatonergic antidepressant to offer a new approach to
the treatment of depression is just over the horizon after new data
demonstrated positive efficacy with marked improvements in sleep
with no effect on daytime vigilance.
A new class of antipressant - dubbed the triple reuptake inhibitor
- will in time come to dominate the market for depression
treatments and achieve multibillion dollar revenues, according to
new market research.
UK-headquartered pharma giant GlaxoSmithKline says it has overcome
the manufacturing problems that caused it to voluntarily withdraw
its antidepressant Paxil CR (paroxetine) and diabetes drug
Avandamet (metformin and rosiglitazone)...
A new type of antidepressant drug with a novel mechanism of action,
which acts on a new target, has entered Phase I clinical trials.
The drug could represent a new generation of psycho-active
compounds that are devoid of the problems...
Worldwide efforts to produce a newer, safer antidepressant have
never been more imperative after a US landmark ruling requires all
antidepressant drugs to carry the strongest possible warning,
informing the public of the risks of...
A case currently going through the European Court of Justice could
have worrying implications for companies that use reformulation and
drug delivery as a way to extend the patented lifespan of their